Samsung Bioepis Presents Phase 1 and 3 Clinical Results for
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced...
British Columbia United States Denosumab Biosimilar Ilsun Hong Samsung Bioepis Samsung Bioepis Co Ltd
Source: globenewswire.com